Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

Panelists discuss how, coming into ASH 2024, the largest unmet needs in the treatment and management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) include improving outcomes for treatment-naive patients, with a focus on emerging Bruton tyrosine kinase inhibitor (BTKi) regimens such as acalabrutinib plus venetoclax, pirtobrutinib plus venetoclax, and zanubrutinib combinations.

Now Viewing

EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP: 3.Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

Video content above is prompted by the following:

1. Coming into ASH 2024, what would you consider to be the largest unmet needs in the treatment and management of CLL and MCL?
2. Provide an overview of the following emerging BTKi treatment regimens in treatment-naive patients with CLL. 

Related Videos